Replay available

Fate Therapeutics, Inc. (FATE) Q3 2023 Earnings Call

Fate Therapeutics, Inc. (NASDAQ: FATE) Q3 2023 earnings conference call, held 2023-11-08. Replay captured from the company's public earnings webcast.

Wed, November 8, 2023 at 5:00 PMendedReplay
Fate Therapeutics, Inc. (FATE) Q3 2023 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Mara Goldstein

Mizuho

Ed Duloc

Chief Financial Officer

Peter Lawson

Barclays

Scott Wolko

President and CEO

Tyler Van Buren

TD Cohen

Ashik Mubarak

on behalf of Yagal Nakamovitz (Citi)

Dana Graybosh

Learing Partners

Ezra Dorout

BMO Capital Markets

Yanan Zhu

Wells Fargo

Unknown Participant

Replay transcript excerpt

Welcome to the FATE Therapeutics Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. The call is being webcast live on the Investors section of FATE's website at fatetherapeutics.com. As a reminder, today's call is being recorded. I would now like to introduce Scott Wolko, President and CEO of FATE Therapeutics. Thank you. Good afternoon and thanks everyone for joining us for the FAPE Therapeutics third quarter 2023 financial results call. Shortly after 4 p.m. Eastern time today, we issued a press release with these results, which can be found on the investor section of our website under press releases. In addition, our form 10-Q for the quarter ended September 30, 2023 was filed shortly thereafter and can be found on the Investors section of our website under Financial Information. Before we begin, I would like to remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Please see the forward-looking statement disclaimer on the company's earnings press release issued after the close of market today, as well as the risk factors included in our Form 10-Q for the quarter ended September 30, 2023 that was filed with the FCC today. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made as the facts and circumstances underlying these forward-looking statements may change. Except as required by law, state...

More from Fate Therapeutics, Inc.